TrialHepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Trial details
- Registry ID
- NCT04057040
- Phase
- Phase 2
Drug research
PTG-300
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Rusfertide
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)NCT04057040 | PTGX | Phase 2 | Completed | 2023-02-14Actual |
| PTG-300 in Subjects With Hereditary HemochromatosisNCT04202965 | PTGX | Phase 2 | Completed | 2021-10-06Actual |
| PTG-300 in Patients With Polycythemia Vera and Elevated HematocritNCT04767802 | PTGX | Phase 2 | Completed | 2023-03-15Actual |
PTG-300 in Subjects With Hereditary Hemochromatosis
Trial details
- Registry ID
- NCT04202965
- Phase
- Phase 2
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Trial details
- Registry ID
- NCT04767802
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |